Financials

News Discussions Technicals Seasonals

Diluted net income available to common stockholders of REVIVE THERAPEUTICS LTD.

Annual data

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

TTM

‪‪−22.00 M‬‬

‪‪−16.50 M‬‬

‪‪−11.00 M‬‬

‪‪−5.50 M‬‬

‪0.00‬

Period

Value

Change

Change %

TTM

‪‪−5.29 M‬‬

+‪‪324.03 K‬‬

+‪5.77‬%

2024

‪‪−5.62 M‬‬

+‪‪702.28 K‬‬

+‪11.11‬%

2023

‪‪−6.32 M‬‬

+‪‪11.49 M‬‬

+‪64.50‬%

2022

‪‪−17.81 M‬‬

+‪‪2.31 M‬‬

+‪11.49‬%

2021

‪‪−20.12 M‬‬

‪‪−14.74 M‬‬

‪−273.84‬%

2020

‪‪−5.38 M‬‬

‪‪−4.04 M‬‬

‪−300.46‬%

2019

2018

2017

2016

2015

Quarterly data

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪‪−2.80 M‬‬

‪‪−2.10 M‬‬

‪‪−1.40 M‬‬

‪‪−700.00 K‬‬

‪0.00‬

Period

Value

Change

Change %

Q2 '25

‪‪−364.71 K‬‬

+‪‪107.80 K‬‬

+‪22.82‬%

Q1 '25

‪‪−472.51 K‬‬

+‪‪2.11 M‬‬

+‪81.72‬%

Q4 '24

‪‪−2.59 M‬‬

‪‪−713.46 K‬‬

‪−38.11‬%

Q3 '24

‪‪−1.87 M‬‬

‪‪−1.10 M‬‬

‪−142.91‬%

Q2 '24

‪‪−770.62 K‬‬

‪‪−380.00 K‬‬

‪−97.28‬%

Q1 '24

‪‪−390.62 K‬‬

+‪‪801.94 K‬‬

+‪67.24‬%

Q4 '23

‪‪−1.19 M‬‬

+‪‪751.52 K‬‬

+‪38.66‬%

Q3 '23

‪‪−1.94 M‬‬

‪‪−419.13 K‬‬

‪−27.49‬%

Q2 '23

Q1 '23

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19

Q3 '19

Q2 '19

Q1 '19

Q4 '18

Q3 '18

Q2 '18

Q1 '18

Q4 '17